Post-COVID Interstitial Lung Disease - The Looming Epidemic

Area of Science:

• Pulmonology
• Infectious Diseases
• Radiology

Background:

• Sequelae of COVID-19 pandemic present challenges, including pulmonary fibrosis causing breathlessness.
• Current management for post-COVID-19 pulmonary fibrosis is primarily symptomatic and underexplored.
• Pulmonary complications like interstitial lung disease (ILD) are a growing concern in COVID-19 survivors.

Purpose of the Study:

• To highlight the emerging threat of post-COVID-19 interstitial lung disease (PC-ILD) in individuals recovering from COVID-19.
• To present a case series illustrating the development of PC-ILD.
• To emphasize the need for increased clinical attention to this complication.

Main Methods:

• Retrospective analysis of patients admitted with severe COVID-19.
• Inclusion criteria: prolonged symptoms and signs suggestive of pulmonary fibrosis post-hospitalization.
• High-resolution computed tomography (HRCT) used for diagnosing pulmonary fibrosis/ILD in three identified patients.

Main Results:

• Three laboratory-proven SARS-CoV-2 positive cases developed pulmonary fibrosis with traction bronchiectasis, identified as PC-ILD.
• Two patients survived with improved oxygen saturation at three-month follow-up.
• One patient experienced fatal arrhythmia.

Conclusions:

• Post-COVID-19 interstitial lung disease (PC-ILD) is an emerging complication of COVID-19 pneumonia.
• Proactive follow-up programs are essential for early detection and management of PC-ILD.
• Addressing this potential epidemic requires systematic monitoring of COVID-19 survivors.